Humanigen Inc (HGENQ)

[nort_lorfer]

HGEN investors are counting on successful results from the ACTIV trial to bolster EUA application. However, if I'm reading correctly (on the gov website), you are right and those in the trial will include ordinal scale 5,6,7.

If there are patients with CRP>150, and lenz doesn't treat that subset well, this will have a negative effect on overall data.

I'm a bit confused between the trial design (supposedly in lenzilumab favor) but while including patients that lenz does not treat well?